KCNH2 and COVID-19: The anti-viral efficacy of these drugs is unconfirmed (and is under considerable scrutiny), whereas both drugs are known to exhibit pro-arrhythmic and arrhythmic levels of hERG blockade in the clinical setting (based on data from the Federal Adverse Event Reporting System summarized in [49], a recent COVID-19 patient cohort [50], and reports of QT prolongation in COVID-19 patients [51,52]).